Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Telitacicept
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2020
Details:
US FDA granted Fast Track designation for RC18, for the treatment of systemic lupus erythematosus (SLE). RC18 shows statistically significant improvement for patients at multiple doses.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
